Evans L, George T, O'Sullivan B, Mitchell P, Johnson G, Adena M
University of Queensland, Brisbane.
Aust N Z J Psychiatry. 1992 Sep;26(3):454-8. doi: 10.3109/00048679209072070.
This paper reports the results of a multicentre study of the new monoamine oxidase inhibitor, moclobemide, in the treatment of major depression. Moclobemide is a specific monoamine oxidase-A inhibitor which does not bind irreversibly to the enzyme, unlike the currently available MAOIs. Recent studies would suggest that in subjects taking moclobemide blood pressure elevation caused by tyramine is significantly less than that induced by the irreversible MAOIs, particularly when tyramine is administered in an oral form. Forty-eight patients with major depression were randomly allocated to treatment with either moclobemide or amitriptyline for 4 weeks in a double-blind comparison. There were no statistically significant differences between the two groups on measures of efficacy. Patients taking amitriptyline reported a greater number of side-effects and more patients in the amitriptyline group dropped out because of these. There were no reports of interactions with tyramine-containing foods.
本文报告了一项关于新型单胺氧化酶抑制剂吗氯贝胺治疗重度抑郁症的多中心研究结果。吗氯贝胺是一种特异性单胺氧化酶-A抑制剂，与目前可用的单胺氧化酶抑制剂不同，它不会与该酶不可逆结合。最近的研究表明，服用吗氯贝胺的受试者因酪胺引起的血压升高明显低于不可逆单胺氧化酶抑制剂所致，尤其是口服酪胺时。48例重度抑郁症患者被随机分配，在双盲对照中接受吗氯贝胺或阿米替林治疗4周。两组在疗效指标上无统计学显著差异。服用阿米替林的患者报告的副作用更多，且阿米替林组有更多患者因这些副作用而退出。未报告与含酪胺食物相互作用的情况。
